Correlation Between SAB Biotherapeutics and GlycoMimetics
Can any of the company-specific risk be diversified away by investing in both SAB Biotherapeutics and GlycoMimetics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SAB Biotherapeutics and GlycoMimetics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between SAB Biotherapeutics and GlycoMimetics, you can compare the effects of market volatilities on SAB Biotherapeutics and GlycoMimetics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SAB Biotherapeutics with a short position of GlycoMimetics. Check out your portfolio center. Please also check ongoing floating volatility patterns of SAB Biotherapeutics and GlycoMimetics.
Diversification Opportunities for SAB Biotherapeutics and GlycoMimetics
-0.15 | Correlation Coefficient |
Good diversification
The 3 months correlation between SAB and GlycoMimetics is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding SAB Biotherapeutics and GlycoMimetics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on GlycoMimetics and SAB Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SAB Biotherapeutics are associated (or correlated) with GlycoMimetics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of GlycoMimetics has no effect on the direction of SAB Biotherapeutics i.e., SAB Biotherapeutics and GlycoMimetics go up and down completely randomly.
Pair Corralation between SAB Biotherapeutics and GlycoMimetics
Assuming the 90 days horizon SAB Biotherapeutics is expected to generate 3.81 times more return on investment than GlycoMimetics. However, SAB Biotherapeutics is 3.81 times more volatile than GlycoMimetics. It trades about 0.04 of its potential returns per unit of risk. GlycoMimetics is currently generating about -0.01 per unit of risk. If you would invest 7.74 in SAB Biotherapeutics on December 30, 2024 and sell it today you would lose (4.25) from holding SAB Biotherapeutics or give up 54.91% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 90.32% |
Values | Daily Returns |
SAB Biotherapeutics vs. GlycoMimetics
Performance |
Timeline |
SAB Biotherapeutics |
GlycoMimetics |
SAB Biotherapeutics and GlycoMimetics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with SAB Biotherapeutics and GlycoMimetics
The main advantage of trading using opposite SAB Biotherapeutics and GlycoMimetics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SAB Biotherapeutics position performs unexpectedly, GlycoMimetics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GlycoMimetics will offset losses from the drop in GlycoMimetics' long position.SAB Biotherapeutics vs. SAB Biotherapeutics | SAB Biotherapeutics vs. NRx Pharmaceuticals | SAB Biotherapeutics vs. Surrozen Warrant |
GlycoMimetics vs. Mineralys Therapeutics, Common | GlycoMimetics vs. Foghorn Therapeutics | GlycoMimetics vs. Inventiva Sa | GlycoMimetics vs. Dyne Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |